Gain insights into RxSight's Q1 2025 earnings highlights, revised guidance, market challenges, and growth strategies.

RxSight, Inc. (NASDAQ:RXST) shares are trading lower premarket on Thursday. On Wednesday, the company disclosed first-quarter ...

BofA has lowered the price target from $36 to $22. RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+) in the first quarter, missing Street estimates by 9%. The year over year ...

The brokerage highlighted that RxSight’s first-quarter performance saw a sequential revenue decline of around 6% compared to the fourth quarter of 2024. Sales of Light Adjustable Lenses (LALs ...

The sale of 27,579 Light Adjustable Lenses (LAL™/LAL+ ®); representing a 36% increase in procedure volume compared to the first quarter of 2024; and The sale of 73 Light Delivery Devices (LDD™s), ...

April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic ... The sale of 27,579 Light Adjustable Lenses (LAL™/LAL+ ®); representing a 36% increase in procedure volume ...

RxSight (RXST, Financials ... The California-based maker of light-adjustable intraocular lenses expects revenue of $37.9 million for the first quarter of 2025, representing 28% year-over-year ...

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the ...

RxSight (NASDAQ:RXST ... manufacture and sale of light adjustable lenses and related capital equipment. Market Capitalization Perspectives: The company's market capitalization falls below industry ...